Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 2, 2004, Pages 327-343

  Bredeson, Christopher N ^a   Pavletic, Steven Z ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmune diseases; Clinical trials; Controlled clinical trials; Data safety and monitoring boards; Equipoise; Haematopoietic stem cell transplantation; Outcome measures; Phase II; Sample size

Indexed keywords

BIOLOGICAL MARKER; HLA ANTIGEN; MITOXANTRONE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; DATA BASE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LONGITUDINAL STUDY; MEDICAL EXPERT; METHODOLOGY; MULTIPLE SCLEROSIS; PATIENT CARE; PATIENT MONITORING; PHYSICIAN; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; PATIENT SELECTION; RESEARCH DESIGN; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 4344695934     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.04.007     Document Type: Article

References (39)

1. Meinert C.L. Clinical Trials: Design, Conduct and Analysis 1986 Oxford University Press New York
2. Devereaux P.J. Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making Journal of Internal Medicine 254 2003 105-113
3. Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents Chest 95 1989 2S-4S
4. Gale R.P. Büchner T. Zhang M.-J. et al. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission Leukemia 10 1996 1687-1691
5. Berry D.A. Broadwater G. Klein J.P. et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of cancer and leukemia group B trials with data from the Autologous Blood and Marrow Transplant Registry Journal of Clinical Oncology 20 2002 743-750
6. Steinberg S.M. Venzon D.J. Early selection in a randomized phase II clinical trial Statistics in Medicine 21 2002 1711-1726
7. Berry D.A. A case for Bayesianism in clinical trials (with discussion) Statistics in Medicine 12 1993 1377-1404
8. Berry D.A. Statistics: A Bayesian Perspective 1996 Duxbury Press Belmont, CA
9. Clements P.J. Furst D.E. Choosing appropriate patients with SSc for treatment by autologous stem cell transplantation Journal of Rheumatology 24 supplement 48 1997 85-88
10. Bulpitt K.J. Clements P.J. Lachenbruch P.A. et al. Early undifferentiated connective tissue disease. III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis) Annals of Internal Medicine 118 1993 602-609
11. Hahn B.H. The potential role of autologous stem cell transplantation in patients with SLE Journal of Rheumatology 24 supplement 48 1997 89-93
12. Tyndall A. Hematopoietic stem cell transplantation in rheumatic diseases other than SSc and SLE Journal of Rheumatology 24 supplement 48 1997 94-97
13. Devereaux P.J. Anderson D.R. Gardner M.J. et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study British Medical Journal 323 2001 1218-1222
14. McAlister F.A. O'Connor A.M. Wells G. et al. When should hypertension be treated? The different perspective of Canadian family physicians and patients Canadian Medical Association Journal 162 2000 403-408
15. Slevin M.L. Stubbs L. Plant H.J. et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors nurses, and general public British Medical Journal 300 1990 1458-1560
16. Snowden J.A. Nivison-Smith I. Biggs J.C. Brooks P.M. Risk taking in patients with rheumatoid arthritis: are the risks of haemopoietic stem cell transplantation acceptable? Rheumatology 38 1999 321-324
17. Verburg R.J. Mahabali S.D. Stiggelbout A.M. et al. High dose chemotherapy and hematopoietic stem cell transplantation: a study of treatment preference in patients with rheumatoid arthritis and rheumatologists Journal of Rheumatology 29 2002 1653-1658
18. Wells G.A. Tugwell P. Kraag G.R. et al. Minimum important differences between patients with rheumatoid arthritis: the patient's perspective Journal of Rheumatology 20 1993 557-560
19. Jaeshke R. Singer J. Guyatt G.H. Measurement of health status: ascertaining the minimal clinically important difference Controlled Clinical Trials 10 1989 407-415
20. Verburg R.J. Sont J.K. Vleit Vlieland T.P. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis Journal of Rheumatology 28 2001 719-727
21. Zaffaroni M. Biological indicators of the neurodegenerative phase of multiple sclerosis Neurological Science 24 supplement 5 2003 S279-S282
22. Uccelli A. Pedemonte E. Narciso E. Mancardi G. Biological markers of the inflammatory phase of multiple sclerosis Neurological Science 24 supplement 5 2003 S271-S274
23. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clinical Pharmacology and Therapeutics 69 2001 89-95
24. Fleming T.R. DeMets D.L. Surrogate end points in clinical trials Annals of Internal Medicine 125 1996 605-613
25. Burt R.K. Cohen B.A. Russell E. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores Blood 102 2003 2373-2378
26. Nash R.A. Bowen J.D. McSweeney P.A. et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis Blood 102 2003 2364-2372
27. Nash R.A. McSweeney P.A. Storb R. Development of a protocol for allogeneic marrow transplantation for severe SSc: paradigm for autoimmune disease Journal of Rheumatology 24 supplement 48 1997 72-78
28. Noseworthy J.H. Ebers G.C. Vandeervoort M.K. et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial Neurology 44 1994 16-20
29. Klein J.P. Rizzo J.D. Zhang M.-J. Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 1. Unadjusted analysis Bone Marrow Transplantation 28 2001 909-915
30. Klein J.P. Rizzo J.D. Zhang M.-J. Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2. Regression modeling Bone Marrow Transplantation 28 2001 1001-1011
31. Piantadosi S. Clinical Trials: A Methodologic Perspective 1997 Wiley New York
32. Machin D. Campbell M. Fayers P. Pinol A. Sample Size Tables for Clinical Studies 2nd edn 1997 Blackwell Science Williston, ND
33. Fazzari M. Heller G. Scher H.I. The phase II/III transition: toward the proof of efficacy in cancer clinical trials Controlled Clinical Trials 21 2000 360-368
34. Klein J.P. Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Data 1997 Springer New York
35. Craddock C. Szydlo R.M. Klein J.P. et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission Blood 96 2000 86-90
36. International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma New England Journal of Medicine 329 1993 987-994
37. Meyer R.M. Browman G.P. Implication of using a prognostic index to select therapy for patients with aggressive histology lymphoma The Canadian Journal of Oncology 5 1995 344-354
38. Laupacis A. Sackett D.L. Roberts R. An assessment of clinically useful measures of the consequences of treatment New England Journal of Medicine 318 1988 1728-1733
39. Hartung H.P. Gonsette R. König N. the Mitoxantrone in Multiple Sclerosis Study Group (MIMS) et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial Lancet 360 2002 2018-2025